
[Federal Register: April 22, 2008 (Volume 73, Number 78)]
[Notices]               
[Page 21632-21633]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22ap08-57]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

 
Joint Meeting of the Anesthetic and Life Support Drugs Advisory 
Committee and the Drug Safety and Risk Management Advisory Committee; 
Amendment of Notice

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of meeting of the Anesthetic and Life Support Drugs 
Advisory Committee and the Drug Safety and Risk Management Advisory 
Committee. This meeting was announced in the Federal Register of March 
27, 2008 (73 FR 16314). The amendment is being made to reflect changes 
in the introductory paragraph and to add a portion entitled ``Closed 
Committee Deliberations.'' There are no other changes.

FOR FURTHER INFORMATION CONTACT: Teresa Watkins, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093), 
Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail:

[[Page 21633]]

Teresa.Watkins@fda.hhs.gov, or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572) in Washington, DC area), codes 3014512529 
and 3014512535. Please call the Information Line for up-to-date 
information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of March 27, 2008, 
FDA announced that a meeting of the Anesthetic and Life Support Drugs 
Advisory Committee and the Drug Safety and Risk Management Advisory 
Committee would be held on May 5 and 6, 2008.
    On page 16314, in the third column, the introductory paragraph of 
the document is amended to read as follows:
    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    On page 16315, the second column of the document is amended to add 
a portion entitled ``Closed Committee Deliberations'' to read as 
follows:
    Closed Committee Deliberations: On May 5, 2008, from 8 a.m. to 9:15 
a.m., the meeting will be closed to permit discussion and review of 
trade secret and/or confidential commercial information (5 U.S.C. 
552b(c)(4)). During this session, the committee will discuss the 
details of a proprietary research report and protocol addressing 
characteristics of different formulations.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: April 16, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8-8683 Filed 4-21-08; 8:45 am]

BILLING CODE 4160-01-S
